Company Overview and News

19
AKBA / Akebia Therapeutics, Inc. 8-K (Current Report)

2018-06-15 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AKBA

216
NBY / NovaBay Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-05-17 fintel.io
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) has 10 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,828,053 shares. Largest shareholders include Op Financial Ltd, Bank Of America Corp /de/, Vanguard Group Inc, BlackRock Inc., Nvwm, Llc, UBS Group AG, Morgan Stanley, Genovese Burford & Brothers Wealth & Retirement Plan Management, LLC, and Royal Bank Of Canada.
NBY GNC MS.PRE CEI MS.PRF RY.PRSCL MS.PRG RBCDF MS.PRA AKBA BAC UBS UBS.PRDCL MS BAC RY ABEO BLK RY MS.PRI MS.PRK RY.PRS ABEOW RY.PRT ULSGF

18
AKBA / Akebia Therapeutics, Inc. 10-Q (Quarterly Report)

2018-05-09 sec.gov
akba-10q_20180331.htm fEDIon of U
AKBA

47
Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

2018-05-08 globenewswire
DEVON, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2018 and provided an overview of recent operational highlights.
ZYNE AKBA

19
AKBA / Akebia Therapeutics, Inc. DEF 14A

2018-04-30 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
AKBA

19
AKBA / Akebia Therapeutics, Inc. DEFA14A

2018-04-30 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AKBA

94
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors

2018-04-16 globenewswire
DEVON, Pa., April 16, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, today announced the appointment of John Butler to its board of directors.
KERX ZYNE BAX AKBA

23
AKBA / Akebia Therapeutics, Inc. 8-K (Current Report)

2018-04-12 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AKBA

17
AKBA / Akebia Therapeutics, Inc. 424B5 (Prospectus)

2018-03-26 sec.gov
424B5 Table of Contents CALCULATION OF REGISTRATION FEE
AKBA

18
AKBA / Akebia Therapeutics, Inc. 8-K (Current Report)

2018-03-26 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AKBA

17
AKBA / Akebia Therapeutics, Inc. 424B5 (Prospectus)

2018-03-22 sec.gov
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223585 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not offers to sell securities and we are
AKBA

18
Akebia Therapeutics' (AKBA) CEO John Butler on Q4 2017 Results - Earnings Call Transcript

2018-03-13 seekingalpha
Good day, ladies and gentlemen, and welcome to Akebia's Fourth Quarter and Full-Year 2017 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded.
AKBA

17
AKBA / Akebia Therapeutics, Inc. 10-K (Annual Report)

2018-03-12 sec.gov
akba-10k_20171231.htm
AKBA

17
AKBA / Akebia Therapeutics, Inc. S-3ASR

2018-03-12 sec.gov
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 12, 2018 Registration No. 333-
AKBA

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 00972D105